The Federal Trade Commission will attempt to stop CSL, Melbourne, Australia, from buying Talecris Biotherapeutics, Research Triangle, N.C., saying the $3.1 billion deal would be bad for competition in the U.S. blood-products market.
Now more than ever, it is critical that consumers benefit from vigorous competition in the healthcare sectorboth to ensure competitive prices and to drive further innovation, Richard Feinstein, the recently appointed director of the FTCs Bureau of Competition, said in a news release.
A federal lawsuit seeking an injunction will be filed in U.S. District Court in Washington in order to block the deal from closing pending an administrative trial. CSL reported in a May 25 statement that the company expected the action after managing director Brian McNamee met with FTC officials in Washington last week.
According to the FTC, Talecris is the worlds third-largest producer of plasma-derivative protein therapies, and CSL is the worlds second-largest. The proposed acquisition would further consolidate the industry and increase the likelihood of collusion, Feinstein said in the release.